Evaxion Announces Phase II Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S announced that the first patient in its EVX-01 Phase II trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA®. The company initiated its Phase II clinical study to assess the efficacy, safety, and ability to induce a tumor-specific immune response of the EVX-01 cancer vaccine in metastatic melanoma patients.